Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Status Recruiting

Clinical Trial Summary

This study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.

Clinical Trial Description

This study is a single-arm, open-label, multicenter, phase II clinical study. Subjects were eligible for screening and entered the trial period after enrollment and received treatment with palbociclib（125mg/day), trastuzumab(8 mg→6mg/every 3 week), pertuzumab(840 mg→420mg/every 3 week), combined with endocrine therapy until disease progression, or intolerable toxicity, or withdrawal of informed consent, or discontinuation of medication at the investigator 's discretion. On-study imaging assessments were performed according to RECIST 1.1 criteria and the site assessment was final. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05969184
Study type	Interventional
Source	Peking University Cancer Hospital & Institute
Contact	Huiping Li, Dr
Phone	01088196380
Email	huipingli2012@hotmail.com
Status	Recruiting
Phase	Phase 2
Start date	December 25, 2021
Completion date	December 25, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03980626` - Study on Physical Activity's Relationship With Cancer and Cognition	N/A
Completed	`NCT04329819` - Satisfaction and QUality of Life After Breast REconstruction
Recruiting	`NCT03323346` - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT03900884` - Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer	Phase 1
Completed	`NCT05042999` - The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures	N/A
Not yet recruiting	`NCT03662633` - Diagnosis Value of SEMA4C in Breast Cancer
Recruiting	`NCT05075512` - The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer	Phase 2
Recruiting	`NCT04456855` - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Not yet recruiting	`NCT03629509` - BEFORE Decision Aid Implementation Study	N/A
Completed	`NCT04811378` - HaemoCerTM Application in Breast Cancer Surgery	N/A
Completed	`NCT03198442` - Breast PET Feasibility	N/A
Not yet recruiting	`NCT05577442` - Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer	Phase 2
Enrolling by invitation	`NCT04047823` - Temperature and Injury in Radiotherapy Radiation Skin Injury
Recruiting	`NCT05452213` - Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients	Phase 4
Recruiting	`NCT05027321` - Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies	N/A
Recruiting	`NCT04812652` - Digitally Distributed Yoga for Women Treated for Breast Cancer	N/A
Active, not recruiting	`NCT03425838` - Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	Phase 3
Completed	`NCT05473026` - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors	N/A
Completed	`NCT04509063` - Investigating Public Enthusiasm for Mammography Screening in Denmark	N/A
Recruiting	`NCT05711030` - Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery	N/A